Fortress Biotech Reports Third Quarter 2026 Revenue Growth Driven by Emrosi Sales
Fortress Biotech (FBIO) reported third-quarter 2026 total revenue of $19 million, representing an 8% increase compared to the previous year. The growth was primarily driven by its dermatology product, Emrosi, which generated $9 million in net sales from 40,000 prescriptions. Clinical data suggests Emrosi is outperforming competitors like Oracea, with a 30% clear-skin achievement rate versus 12.8% for the competitor. The company achieved positive non-GAAP adjusted EBITDA, reporting net income of $3.5 million for the quarter compared to $1.4 million in the prior year period. This profitability was aided by lower manufacturing costs and operating leverage, despite a one-time $1.7 million vendor dispute settlement. Management is currently focused on expanding commercial coverage, which has reached 40% of target market lives, through further health plan formulary additions.
Topics: clinical trial data commercial coverage pharmaceuticals revenue growth